Intra‐tumoral and peripheral blood TIGIT and PD ‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27459 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Jay Gunawardana und 33 weiteren Autor:innen. Beteiligte Einrichtung: Blood Cancer Research Group, Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Hodgkin Disease, Programmed Cell Death 1 Receptor, Receptors, Immunologic, Tumor Microenvironment. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Limerick Digital Cancer Research Centre, Australian National Health and Medical Research Council.
Abstract (Originalsprache)
In classical Hodgkin lymphoma (cHL), responsiveness to immune‐checkpoint blockade (ICB) is associated with specific tumor microenvironment (TME) and peripheral blood features. The role of ICB in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is not established. To gain insights into its potential in NLPHL, we compared TME and peripheral blood signatures between HLs using an integrative multiomic analysis. A discovery/validation approach in 121 NLPHL and 114 cHL patients highlighted >2‐fold enrichment in programmed cell death‐1 (PD‐1) and T‐cell Ig and ITIM domain (TIGIT) gene expression for NLPHL versus cHL. Multiplex imaging showed marked increase in intra‐tumoral protein expression of PD‐1+ (and/or TIGIT+) CD4+ T‐cells and PD‐1+CD8+ T‐cells in NLPHL compared to cHL. This included T‐cells that rosetted with lymphocyte predominant (LP) and Hodgkin Reed–Sternberg (HRS) cells. In NLPHL, intra‐tumoral PD‐1+CD4+ T‐cells frequently expressed TCF‐1, a marker of heightened T‐cell response to ICB. The peripheral blood signatures between HLs were also distinct, with higher levels of PD‐1+TIGIT+ in TH1, TH2, and regulatory CD4+ T‐cells in NLPHL versus cHL. Circulating PD‐1+CD4+ had high levels of TCF‐1. Notably, in both lymphomas, highly expanded populations of clonal TIGIT+PD‐1+CD4+ and TIGIT+PD‐1+CD8+ T‐cells in the blood were also present in the TME, indicating that immune‐checkpoint expressing T‐cells circulated between intra‐tumoral and blood compartments. In in vitro assays, ICB was capable of reducing rosette formation around LP and HRS cells, suggesting that disruption of rosetting may be a mechanism of action of ICB in HL. Overall, results indicate that further evaluation of ICB is warranted in NLPHL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Blood Cancer Research Group, Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.
- School of Medicine, Limerick Digital Cancer Research Centre, Health Research Institute and Bernal Institute, University of Limerick, Limerick, Ireland.
- Royal College of Surgeons Ireland, Adliya, Bahrain.
- Frazer Institute, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.
- Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales, Australia.
- Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.
ORCID-Profile: Jay Gunawardana, Soi C Law, Muhammed B Sabdia, Éanna Fennell, Aoife Hennessy, Ciara I Leahy, Paul G Murray, Karolina Bednarska, Sandra Brosda, Judith Trotman, Dipti Talaulikar, Emily Jude, Eliza A Hawkes, Karthik Nath, Cameron Snell, Fiona Swain, Joshua W D Tobin, Colm Keane, Mohamed Shanavas, Emily Blyth, Christian Steidl, Kerry Savage, Pedro Farinha, Michael R Green, Francisco Vega, Maher K Gandhi
Förderung
- NCI NIH HHS
- Limerick Digital Cancer Research Centre
- Australian National Health and Medical Research Council
- American Society of Hematology
- Medical Research Council
- Mater Foundation
- Cancer Australia Priority-driven Collaborative Cancer Research Scheme (Leukaemia Foundation)
- Leukemia and Lymphoma Society Scholar Award
Zitieren
APA
Gunawardana, J., Law, S. C., Sabdia, M. B., Fennell, É., Hennessy, A., Leahy, C. I., Murray, P. G., Bednarska, K., Brosda, S., Trotman, J., Berkahn, L., Zaharia, A., Birch, S., Burgess, M., Talaulikar, D., Lee, J. N., Jude, E., Hawkes, E. A., Jain, S., …, & Gandhi, M. K. (2024). Intra‐tumoral and peripheral blood TIGIT and PD ‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma. American Journal of Hematology. https://doi.org/10.1002/ajh.27459
Vancouver
Gunawardana J, Law SC, Sabdia MB, Fennell É, Hennessy A, Leahy CI, et al. Intra‐tumoral and peripheral blood TIGIT and PD ‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma. American Journal of Hematology. 2024. doi:10.1002/ajh.27459
BibTeX
@article{Gunawardana2024,
author = {Gunawardana, Jay and Law, Soi C and Sabdia, Muhammed B and Fennell, Éanna and Hennessy, Aoife and Leahy, Ciara I and Murray, Paul G and Bednarska, Karolina and Brosda, Sandra and Trotman, Judith and Berkahn, Leanne and Zaharia, Andreea and Birch, Simone and Burgess, Melinda and Talaulikar, Dipti and Lee, Justina N and Jude, Emily and Hawkes, Eliza A and Jain, Sanjiv and Nath, Karthik and Snell, Cameron and Swain, Fiona and Tobin, Joshua W D and Keane, Colm and Shanavas, Mohamed and Blyth, Emily and Steidl, Christian and Savage, Kerry and Farinha, Pedro and Boyle, Merrill and Meissner, Barbara and Green, Michael R and Vega, Francisco and Gandhi, Maher K},
title = {Intra‐tumoral and peripheral blood TIGIT and PD ‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27459}
}
EUVIMED